What is Solarea Bio?
Solarea Bio, established in 2017 and based in Cambridge, Massachusetts, is dedicated to advancing human health through innovative microbiome-based solutions. The company's core mission is to revolutionize the understanding and application of the human microbiome. Solarea Bio's foundational breakthrough involved identifying a previously untapped source of probiotic microorganisms within healthy foods, and subsequently developing applications for inflammatory processes, particularly focusing on the gut-musculoskeletal axis. This scientific foundation positions Solarea Bio as a key player in the burgeoning field of microbiome therapeutics.
How much funding has Solarea Bio raised?
Solarea Bio has raised a total of $26.2M across 2 funding rounds:
Series A
$11.2M
Series B
$15M
Series A (2020): $11.2M with participation from BOLD Capital Partners, Viking Global Investors, S2G Ventures, and Gisev Family Office
Series B (2023): $15M led by Viking Global Investors, S2G Ventures, and BOLD Capital Partners
Key Investors in Solarea Bio
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies. Viking is headquartered in Greenwich, Connecticut, with offices in New York, Hong Kong, London, and San Francisco.
S2G Ventures
S2G Ventures (Seed 2 Growth) is a multi-stage food and agriculture venture fund investing in entrepreneurs whose products and services meet the shifting demands for healthy and sustainable food. S2G looks for companies that can take leadership positions in emerging and fast growing markets in the food and agriculture sector.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world. They focus on identifying emerging science and technologies that can disrupt and democratize large markets, addressing significant challenges faced by humanity.
What's next for Solarea Bio?
With the recent infusion of major enterprise-level funding and a strategic investment in its Series B round, Solarea Bio is poised for accelerated growth and development. This substantial backing will likely fuel further research and development into its microbiome-based solutions, potentially expanding clinical trials and scaling up its operational capacity. The company's focus on addressing significant health problems through a novel scientific lens, combined with strategic partnerships and capital, suggests a trajectory aimed at commercializing its innovations and making a substantial impact on global health.
See full Solarea Bio company page
